Paul Girolami

He joined Glaxo in 1965 as a Financial Controller. He became finance director in 1968 when aged 42. In April 1980 it was announced that he would become chief executive. In the early 1980s, Glaxo briefly surpassed British Telecom to become Britain's most valued company on the stock market (LSE), and Glaxo was the world's second-largest pharmaceutical company and remained so into the 1990s; it had been 25th largest in the world in 1980. The reasons for this were a huge increase in its R&D budget, and employing many more researchers; by 1993 it was spending $750 million on research with around 5,500 researchers, of which 3,500 were in the UK. Its other researchers were in Italy, the US and Japan. In April 1985 he was appointed as deputy chairman, and it was announced that he would be leaving his post as chief executive in early 1986. On 10 December 1985 he became chairman of Glaxo. He left as chairman in November 1994, when aged 68.[2]

Glaxo merged to become Glaxo Wellcome a year later in 1995. Glaxo drugs that sold well included the Fortum (ceftazidime) and Zinnat (cefuroxime axetil) antibiotics.